GlobeNewsWire
14 Jun 2026, 23:30 UTC · 14w ago
Verdict
Headline takes no side. We score 6855 +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Olverembatinib demonstrated deep and durable responses in CML-CP patients resistant or intolerant to first-line TKI therapy, supporting its potential as a second-line treatment.
More positive than 92% of claims this week
Updated data from the Phase III POLARIS-1 study for olverembatinib in Ph+ ALL further validated its deep response rate and manageable safety profile.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 85% of claims this week
The combination of olverembatinib and lisaftoclax showed encouraging clinical data in pediatric patients with relapsed/refractory Ph+ ALL.
More positive than 76% of claims this week
Registrational Phase II data for lisaftoclax in CLL/SLL provided insights for optimizing individualized dosing regimens.
More positive than 62% of claims this week
Real-world data on lisaftoclax in myeloid neoplasms provided evidence of the drug's clinical utility.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company presented multiple positive clinical updates and robust efficacy data for its core assets at the EHA2026 Congress.
More positive than 83% of ticker scores this week
The company presented multiple positive clinical updates and robust efficacy data for its core assets at the EHA2026 Congress.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4h ago
—
No price for 6855 right now — the quote feed didn't answer.
6855 chart →
